AstraZeneca confirms talks with biotech group Acerta
Pharmaceuticals giant AstraZeneca confirmed that it is exploring potential strategic options with biotech company Acerta Pharma BV.
AstraZeneca
11,720.00p
17:15 26/09/24
1.33%
154.00p
FTSE 100
8,284.91
17:09 26/09/24
n/a
n/a
FTSE 350
4,575.40
17:00 26/09/24
n/a
n/a
FTSE All-Share
4,531.55
17:14 26/09/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,304.02
17:00 26/09/24
0.74%
164.35
“There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction,” AZN said.
The statement follows a report in the Wall Street Journal last week suggesting that the London-listed company was in advanced talks to pay more than $5bn for the cancer drug developer, which is based in California and the Netherlands.